Contact
Please use this form to send email to PR contact of this press release:
Enrollment begins for Sanofi and GSK’s Phase 3 efficacy trial of COVID-19 vaccine candidate in Nepal, led by IVI
TO:
Aerie Em
International Vaccine Institute
+82 2-881-1386